In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Amy ChadburnDepartment of Pathology and Laboratory Medicine, Weill Cornell School of Medicine, New York, NY, USA, 10065.ORCID 0000-0002-9499-8638 Maria Montserrat Aguilar HernandezDepartment of Pathology and Laboratory Medicine, Weill Cornell School of Medicine, New York, NY, USA, 10065.ORCID 0000-0001-8449-4359 Joanne DaiDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA, 27710.ORCID 0000-0002-9879-4704 Mitra HarrisonDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, NC, USA, 27710.ORCID 0009-0003-6976-0120 Nicolas M Reinoso-VizcainoDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA, 27710.ORCID 0000-0002-9769-3768 Ashley P BarryDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA, 27710.
Vaibhav JainMolecular Genomics Core, Duke University, Durham, NC, USA, 27710.
Cliburn ChanDepartment of Biostatistics & Bioinformatics, Duke University School of Medicine, Durham, NC, USA, 27710.ORCID 0000-0001-5901-6806 Ethel CesarmanDepartment of Pathology and Laboratory Medicine, Weill Cornell School of Medicine, New York, NY, USA, 10065.ORCID 0000-0003-3303-6299 Micah A LuftigDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA, 27710.ORCID 0000-0002-2964-1907 Elliott D SoRelleDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA, 27710.ORCID 0000-0002-3362-1028 Funding
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5MRegulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in LymphomaR01CA260691 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CESARMAN, ETHEL, NIXON, DOUGLAS F · 2021 to 2025
$5.8MB cell determinants of EBV latency (supplement)U01CA275301 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Ethel Cesarman, Benjamin Elison Gewurz · 2022 to 2026
$4.0MDefining and exploiting EBV-infected cell heterogeneity in non-Hodgkin lymphomasU01CA275306 · NCI · DUKE UNIVERSITY · PI Micah Alan Luftig · 2022 to 2026
$3.0M(PQ 6) New Models of KSHV Oncogenesis and KS Immune EnvironmentR01CA250074 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CESARMAN, ETHEL · 2020 to 2024
$2.8MNCI NIH HHS R01 CA250074NCI NIH HHS R01 CA260691NCI NIH HHS U01 CA275301NCI NIH HHS U01 CA275306NIAID NIH HHS P30 AI064518
6 · The paper itselfAbstract
Non-Hodgkin Lymphoma (NHL) is the main cancer-related mortality for people living with HIV (PLWH). NHL genetic and molecular classifications have been intensely studied and correlated with clinical outcomes, but critical unanswered questions relevant to malignancy persist. For example, tumors positive for Epstein-Barr virus (EBV) are aggressive and account for 30-50% of HIV-associated NHLs, yet insights on the nature of EBV in NHL pathogenesis or potential therapeutic vulnerabilities have been limited. Here, we examined HIV-associated NHLs stratified by histopathologic classification, cell of origin (COO), molecular subtype, and EBV status using genome-wide spatial transcriptomic analyses. Tumor tissues in EBV
Indexed as
B cell lymphomacell of originEpstein-Barr virusHIVimmunosuppressionnon-Hodgkin lymphomaplasmablastic lymphomapolymorphic lymphoproliferative disorderspatial transcriptomics
Identifiers
PMID41279969
PMCPMC12632762
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390